Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism

Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.114.218560
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for New Therapeutic Approach?

Pancreatic Disorders and Therapy
2015English

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Transforming Growth Factor-Beta. Possible Existence of "Vascular Natriuretic Peptide System".

Journal of Clinical Investigation
Medicine
1992English

Effect of Thanatophoric Dysplasia Type I Mutations on Fibroblast Growth Factor Receptor 3 Dimerization

Biophysical Journal
Biophysics
2015English

Competitive Binding of Musclin to Natriuretic Peptide Receptor 3 With Atrial Natriuretic Peptide

Journal of Endocrinology
EndocrinologyMetabolismDiabetes
2009English

Fibroblast Growth Factor Receptor (FGFR)

Science-Business eXchange
2013English

Therapeutic Potential of Epidermal Growth Factor Receptor-Related Protein

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Fibroblast Growth Factor Receptor 3-IIIc Mediates Colorectal Cancer Growth and Migration

British Journal of Cancer
Cancer ResearchOncology
2010English

C-Type Natriuretic Peptide Restores Impaired Skeletal Growth in a Murine Model of Glucocorticoid-Induced Growth Retardation

Bone
EndocrinologyPhysiologyHistologyMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy